BeyondSpring (NasdaqCM:BYSI) - Share price, News & Analysis

BYSI fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

BYSI Stock Overview

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies.

Rewards

Revenue is forecast to grow 52.17% per year

Risk Analysis

Highly volatile share price over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have meaningful revenue ($1M)

Does not have a meaningful market cap ($54M)

BeyondSpring Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BeyondSpring
Historical stock prices
Current Share Price	US$1.39
52 Week High	US$33.00
52 Week Low	US$1.13
Beta	1.2
1 Month Change	23.01%
3 Month Change	-37.39%
1 Year Change	-87.02%
3 Year Change	-94.14%
5 Year Change	-96.76%
Change since IPO	-91.73%

Shareholder Returns

	BYSI	US Biotechs	US Market
7D	0%	10.3%	6.6%
1Y	-87.0%	-24.4%	-18.5%

Return vs Industry: BYSI underperformed the US Biotechs industry which returned -24.4% over the past year.

Return vs Market: BYSI underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is BYSI's price volatile compared to industry and market?
BYSI volatility
BYSI Average Weekly Movement	17.1%
Biotechs Industry Average Movement	13.0%
Market Average Movement	8.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.1%

Stable Share Price: BYSI is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: BYSI's weekly volatility has decreased from 30% to 17% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2010	103	Lan Huang	https://www.beyondspringpharma.com

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company’s lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers.

BeyondSpring Fundamentals Summary

How do BeyondSpring's earnings and revenue compare to its market cap?
BYSI fundamental statistics
Market Cap	US$54.11m
Earnings (TTM)	-US$64.18m
Revenue (TTM)	US$1.35m

40.1x

P/S Ratio

-0.8x

P/E Ratio

Is BYSI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
BYSI income statement (TTM)
Revenue	US$1.35m
Cost of Revenue	US$0
Gross Profit	US$1.35m
Other Expenses	US$65.53m
Earnings	-US$64.18m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-1.65
Gross Margin	100.00%
Net Profit Margin	-4,750.48%
Debt/Equity Ratio	5.9%

How did BYSI perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is BYSI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BYSI?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for BYSI. This is calculated by dividing BYSI's market cap by their current preferred multiple.
What is BYSI's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	US$54.11m

BYSI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does BYSI's PS Ratio compare to its peers?

BYSI PS Ratio vs Peers

The above table shows the PS ratio for BYSI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PS	Estimated Growth	Market Cap
Peer Average	19.4x

Forward PS

Price-To-Sales vs Peers: BYSI is expensive based on its Price-To-Sales Ratio (40.1x) compared to the peer average (19.4x).

Price to Earnings Ratio vs Industry

How does BYSI's PE Ratio compare vs other companies in the U.S. Biotechs Industry?

Price-To-Sales vs Industry: BYSI is expensive based on its Price-To-Sales Ratio (40.1x) compared to the US Biotechs industry average (14.1x)

Price to Sales Ratio vs Fair Ratio

What is BYSI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BYSI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	40.1x
Fair PS Ratio	129.6x

Price-To-Sales vs Fair Ratio: BYSI is good value based on its Price-To-Sales Ratio (40.1x) compared to the estimated Fair Price-To-Sales Ratio (129.6x).

Share Price vs Fair Value

What is the Fair Price of BYSI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BYSI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BYSI's fair value for valuation analysis.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BYSI's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is BeyondSpring forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

8.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BYSI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BYSI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BYSI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BYSI's revenue (52.2% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: BYSI's revenue (52.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BYSI's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has BeyondSpring performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-2.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BYSI is currently unprofitable.

Growing Profit Margin: BYSI is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: BYSI is unprofitable, and losses have increased over the past 5 years at a rate of 2.4% per year.

Accelerating Growth: Unable to compare BYSI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BYSI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: BYSI has a negative Return on Equity (-258.59%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is BeyondSpring's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BYSI's short term assets ($75.1M) exceed its short term liabilities ($15.2M).

Long Term Liabilities: BYSI's short term assets ($75.1M) exceed its long term liabilities ($40.1M).

Debt to Equity History and Analysis

Debt Level: BYSI has more cash than its total debt.

Reducing Debt: Insufficient data to determine if BYSI's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BYSI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BYSI has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 23.5% each year.

Discover healthy companies

Dividend

What is BeyondSpring current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BYSI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BYSI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BYSI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BYSI's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BYSI has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure

CEO

Lan Huang (50 yo)

7.58yrs

Tenure

Dr. Lan Huang, Ph D., co-founded BeyondSpring Pharmaceuticals, Inc. in 2013 and serves as its Chairman and Chief Executive Officer. Dr. Huang Co-founded BeyondSpring Inc. and has been its Chairman and Chi...

Leadership Team

Experienced Management: BYSI's management team is considered experienced (2.6 years average tenure).

Board Members

Experienced Board: BYSI's board of directors are considered experienced (5.7 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/06/25 00:00
End of Day Share Price	2022/06/24 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31